Provided by Tiger Fintech (Singapore) Pte. Ltd.

AMN Healthcare Services Inc

22.59
-0.7600-3.25%
Volume:26.96K
Turnover:615.11K
Market Cap:862.95M
PE:-5.87
High:23.29
Open:22.74
Low:22.58
Close:23.35
Loading ...

AMN Healthcare Names Tomya Watt as Chief People Officer

THOMSON REUTERS
·
31 Oct 2024

Press Release: AMN Healthcare Names Tomya Watt as Chief People Officer

Dow Jones
·
31 Oct 2024

Earnings Preview: AMN Healthcare Services (AMN) Q3 Earnings Expected to Decline

Zacks
·
31 Oct 2024

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2024

PR Newswire
·
29 Oct 2024

Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire
·
24 Oct 2024

AMN Healthcare price target lowered to $50 from $70 at Truist

TipRanks
·
22 Oct 2024

AMN Healthcare price target lowered to $57 from $66 at JMP Securities

TIPRANKS
·
22 Oct 2024

AMN Healthcare Is Maintained at Buy by Truist Securities

Dow Jones
·
21 Oct 2024

Truist Cuts Price Target on AMN Healthcare Services to $50 From $70, Keeps Buy Rating

MT Newswires Live
·
21 Oct 2024

Is AMN Healthcare Services, Inc.'s (NYSE:AMN) 11% ROE Strong Compared To Its Industry?

Simply Wall St.
·
17 Oct 2024

Viking Therapeutics to Report Financial Results for Third Quarter 2024 on October 23, 2024

PR Newswire
·
17 Oct 2024

Agrimin Says Alec Pismiris Will Remain As Non-Executive Chair Until Upcoming Meeting

T-Reuters
·
14 Oct 2024

AMN Healthcare Services Inc (AMN) Q2 2024 Earnings Call Highlights: Navigating Revenue Declines ...

GuruFocus.com
·
10 Oct 2024

Viking Therapeutics reports positive data from trial of treatment for rare metabolic disorder X-ALD

Dow Jones
·
10 Oct 2024

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

Benzinga
·
09 Oct 2024

AMN Healthcare Services Inc : Bmo Cuts Target Price to $50 From $71

THOMSON REUTERS
·
09 Oct 2024

Viking Therapeutics' stock pops on news of positive data from trial of treatment for rare metabolic disorder X-ALD

Dow Jones
·
09 Oct 2024

Viking Therapeutics' Stock Pops On News Of Positive Data From Trial Of Treatment For Rare Metabolic Disorder X-ALD -- MarketWatch

Dow Jones
·
09 Oct 2024

Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD

PR Newswire
·
09 Oct 2024

AMN Stock Down Despite WorkWise Launch to Enhance Healthcare Delivery

Zacks
·
09 Oct 2024